Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Cantargia AB ( (SE:CANTA) ) has issued an announcement.
Cantargia AB announced the publication of preclinical data in Cancer Discovery, highlighting nadunolimab’s potential to counteract tumor-driven systemic immunosuppression. The study, conducted by Professor Douglas Hanahan’s team, shows that targeting IL1RAP can inhibit tumor-induced immune suppression, with clinical data supporting these findings. The research suggests that nadunolimab could enhance cancer treatment by overcoming resistance to immune therapies, potentially improving outcomes for patients with high neutrophil counts.
More about Cantargia AB
Cantargia AB is a biotechnology company that develops antibody-based treatments for life-threatening diseases. It has established a platform based on the protein IL1RAP, which is involved in various cancer forms and inflammatory diseases. The company’s oncology program focuses on the antibody nadunolimab (CAN04), primarily studied in combination with chemotherapy for pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer. Cantargia also has a development program for the antibody CAN10, targeting autoimmune/inflammatory diseases.
YTD Price Performance: -2.61%
Average Trading Volume: 2,500
Technical Sentiment Signal: Buy
Current Market Cap: €36.77M
See more insights into CANTA stock on TipRanks’ Stock Analysis page.